Cited 18 times in
The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석민 | - |
dc.contributor.author | 박성하 | - |
dc.contributor.author | 이상학 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 정남식 | - |
dc.contributor.author | 최동훈 | - |
dc.date.accessioned | 2014-12-20T16:26:01Z | - |
dc.date.available | 2014-12-20T16:26:01Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0160-9289 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/92707 | - |
dc.description.abstract | BACKGROUND: Many of the pleiotropic effects of statins remain to be elucidated. HYPOTHESIS: Different statin regimens with similar lipid-lowering efficacy may have different effects on biomarkers of atherothrombosis including lipoprotein-associated phospholipase A₂ (Lp-PLA₂ ). METHODS: After a 4-week dietary lead-in, 82 hypercholesterolemic patients were randomized to 1 of 2 treatment groups: atorvastatin 20 mg or atorvastatin/ezetimibe 5 mg/5 mg. After 8 weeks of drug treatment, the groups were compared for percent change in lipid parameters, Lp-PLA₂ , interleukin-6 (IL-6), monocyte chemoattractant protein-1, and fibrinogen. RESULTS: Low-density lipoprotein cholesterol (LDL-C) lowering was comparable between the 2 groups (-47% ± 11% and -49% ± 7% in the atorvastatin and combination groups, respectively). Although Lp-PLA₂ was reduced in both groups, the reduction was greater in the atorvastatin group (-42% and -9% [median], respectively, P = 0.03). Although IL-6 was decreased only in the atorvastatin group, IL-6 changes were not significantly different between the 2 groups. The changes in monocyte chemoattractant protein-1 and fibrinogen were similar in each group. CONCLUSIONS: Atorvastatin monotherapy was stronger at reducing plasma Lp-PLA₂ than the low-dose atorvastatin/ezetimibe combination after equivalent LDL-C lowering. This result may provide evidence of potential statin effects beyond the lowering of LDL-C. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 108~112 | - |
dc.relation.isPartOf | CLINICAL CARDIOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | 1-Alkyl-2-acetylglycerophosphocholine Esterase/blood* | - |
dc.subject.MESH | 1-Alkyl-2-acetylglycerophosphocholine Esterase/drugeffects | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Anticholesteremic Agents/administration & dosage | - |
dc.subject.MESH | Anticholesteremic Agents/therapeutic use* | - |
dc.subject.MESH | Atorvastatin Calcium | - |
dc.subject.MESH | Azetidines/administration & dosage | - |
dc.subject.MESH | Azetidines/therapeutic use* | - |
dc.subject.MESH | Biomarkers, Pharmacological/blood | - |
dc.subject.MESH | Chemokine CCL2/metabolism | - |
dc.subject.MESH | Cholesterol, LDL/blood | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Ezetimibe | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Fibrinogen/metabolism | - |
dc.subject.MESH | Heptanoic Acids/administration & dosage | - |
dc.subject.MESH | Heptanoic Acids/therapeutic use* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use* | - |
dc.subject.MESH | Hypercholesterolemia/blood | - |
dc.subject.MESH | Hypercholesterolemia/drug therapy* | - |
dc.subject.MESH | Interleukin-6/blood | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Pyrroles/administration & dosage | - |
dc.subject.MESH | Pyrroles/therapeutic use* | - |
dc.subject.MESH | Treatment Outcome | - |
dc.subject.MESH | Young Adult | - |
dc.title | The effects of statin monotherapy and low-dose statin/ezetimibe on lipoprotein-associated phospholipase A₂ | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Sang-Hak Lee | - |
dc.contributor.googleauthor | Seok-Min Kang | - |
dc.contributor.googleauthor | Sungha Park | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Namsik Chung | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.identifier.doi | 10.1002/clc.20853 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00037 | - |
dc.contributor.localId | A01512 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A03585 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A02833 | - |
dc.relation.journalcode | J00565 | - |
dc.identifier.eissn | 1932-8737 | - |
dc.identifier.pmid | 21298654 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1002/clc.20853/abstract | - |
dc.contributor.alternativeName | Kang, Seok Min | - |
dc.contributor.alternativeName | Park, Sung Ha | - |
dc.contributor.alternativeName | Lee, Sang Hak | - |
dc.contributor.alternativeName | Jang, Yang Soo | - |
dc.contributor.alternativeName | Chung, Nam Sik | - |
dc.contributor.alternativeName | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Kang, Seok Min | - |
dc.contributor.affiliatedAuthor | Park, Sung Ha | - |
dc.contributor.affiliatedAuthor | Jang, Yang Soo | - |
dc.contributor.affiliatedAuthor | Chung, Nam Sik | - |
dc.contributor.affiliatedAuthor | Choi, Dong Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Snag Hak | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 34 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 108 | - |
dc.citation.endPage | 112 | - |
dc.identifier.bibliographicCitation | CLINICAL CARDIOLOGY, Vol.34(2) : 108-112, 2011 | - |
dc.identifier.rimsid | 28709 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.